In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Affiliations

• ¹ Department of Hematology, Odense University Hospital, Odense, Denmark. Thomas.Lund2@rsyd.dk.
• ² Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Thomas.Lund2@rsyd.dk.
• ³ Department of Hematology, Odense University Hospital, Odense, Denmark.
• ⁴ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
• ⁵ Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
• ⁶ Department of Blood and Cancer Diseases, Stavanger University Hospital, Stavanger, Norway.
• ⁷ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
• ⁸ Department of Radiology, Odense University Hospital, Odense, Denmark.
• ⁹ Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
• ¹⁰ Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
• ¹¹ Department of Hematology, St. Olavs Hospital and Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
• ¹² Karolinska Institutet, Stockholm, Sweden.
• ¹³ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
• ¹⁴ K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, Norway.